Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.

Particle Sciences will have commercial manufacturing capabilities operating at its Pennsylvania facility by the end of the year and will add 30 jobs.

Argentina's Sinergium Biotech, which is in a consortium to develop a Zika virus vaccine, intends to build a new plant that will use cell biology that can…

Israeli biotech BiondVax is looking toward the day when its universal flu vaccine will be commercially available and has snagged some government help to…

The FDA and the European Medicines Agency have agreed to recognize the plant inspections each does in their own areas.

Thanks to some crafty payer negotiating from GSK, even if Advair generics win approval, it may be a while before they gain serious traction, even if it wins…

Sanofi and Swiss contractor Lonza will share the cost of building a €270 million ($286.3 million) plant to expand capacity for new biologic meds.

South San Francisco-based Portola Pharmaceuticals has snagged $50 million in loans from Pfizer and Bristol-Myers Squibb to help cover the additional costs tied…